Welcome to our dedicated page for Turbogen Ltd. SEC filings (Ticker: TRBG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Turbogen Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Turbogen Ltd.'s regulatory disclosures and financial reporting.
Turbogen Ltd. (TRBG) reported the initial holdings of director Eli Zooker. He holds a share option to acquire 30,177 ordinary shares at an exercise price of $2.99 per share, granted on March 9, 2025 and expiring on March 9, 2032. The options vest in three equal installments of 33.3% beginning March 9, 2025; as of August 25, 2026, 20,118 options are fully vested and none have been exercised.
Turbogen Ltd. (TRBG) reported the initial equity holdings of director Deri David. He holds 36,123 ordinary shares directly and options over 30,177 ordinary shares.
The options were granted on March 9, 2025, with an exercise price of NIS 8.95 per share, which for this report was converted to $2.99 per share using an exchange rate of NIS 2.994 to $1.00 as of August 24, 2026. They vest in three equal installments of 33.3% beginning March 9, 2025; as of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares.
Turbogen Ltd. (TRBG) filed an initial statement of beneficial ownership for director Alex Katz. The filing reports that Katz holds 1,134,602 ordinary shares of Turbogen Ltd. directly after the reported event. No specific purchase or sale transaction, price information, or derivative securities are disclosed.